ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oligonucleotide Drug CDMO Services Market Research Report 2026
Published Date: 2026-01-29
|
Report Code: QYRE-Auto-17W18586
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Oligonucleotide Drug CDMO Services Market Research Report 2024
BUY CHAPTERS

Global Oligonucleotide Drug CDMO Services Market Research Report 2026

Code: QYRE-Auto-17W18586
Report
2026-01-29
Pages:122
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bachem
WuXi TIDES
Ajinomoto
Waters
AGC Biologics
Merck KGaA
EUROAPI
CordenPharma
Cytiva
TriLink BioTechnologies
Medicilon
General Biol
Biospring
Bio-Synthesis, Inc.
Aurisco
Porton
Suzhou Olipharma Co.,Ltd
RIBOPharm

Oligonucleotide Drug CDMO Services Market

The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
The North American market for Oligonucleotide Drug CDMO Services is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Oligonucleotide Drug CDMO Services is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Oligonucleotide Drug CDMO Services in SME Pharmaceutical Company is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Oligonucleotide Drug CDMO Services include Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma, Cytiva, TriLink BioTechnologies, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Oligonucleotide Drug CDMO Services market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oligonucleotide Drug CDMO Services. The Oligonucleotide Drug CDMO Services market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Oligonucleotide Drug CDMO Services market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Oligonucleotide Drug CDMO Services manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Oligonucleotide Drug CDMO Services Market Report

Report Metric Details
Report Name Oligonucleotide Drug CDMO Services Market
Segment by Type
  • API
  • Preparation
Segment by Application
  • SME Pharmaceutical Company
  • Large Pharmaceutical Company
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma, Cytiva, TriLink BioTechnologies, Medicilon, General Biol, BioSpring, Bio-Synthesis Inc, Aurisco, Suzhou Olipharma Co.,Ltd, Porton, RIBOPharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Oligonucleotide Drug CDMO Services companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Oligonucleotide Drug CDMO Services Market report?

Ans: The main players in the Oligonucleotide Drug CDMO Services Market are Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma, Cytiva, TriLink BioTechnologies, Medicilon, General Biol, BioSpring, Bio-Synthesis Inc, Aurisco, Suzhou Olipharma Co.,Ltd, Porton, RIBOPharm

What are the Application segmentation covered in the Oligonucleotide Drug CDMO Services Market report?

Ans: The Applications covered in the Oligonucleotide Drug CDMO Services Market report are SME Pharmaceutical Company, Large Pharmaceutical Company

What are the Type segmentation covered in the Oligonucleotide Drug CDMO Services Market report?

Ans: The Types covered in the Oligonucleotide Drug CDMO Services Market report are API, Preparation

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Drug CDMO Services Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 API
1.2.3 Preparation
1.3 Market by Application
1.3.1 Global Oligonucleotide Drug CDMO Services Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 SME Pharmaceutical Company
1.3.3 Large Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Drug CDMO Services Market Perspective (2021–2032)
2.2 Global Oligonucleotide Drug CDMO Services Growth Trends by Region
2.2.1 Global Oligonucleotide Drug CDMO Services Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Oligonucleotide Drug CDMO Services Historic Market Size by Region (2021–2026)
2.2.3 Oligonucleotide Drug CDMO Services Forecasted Market Size by Region (2027–2032)
2.3 Oligonucleotide Drug CDMO Services Market Dynamics
2.3.1 Oligonucleotide Drug CDMO Services Industry Trends
2.3.2 Oligonucleotide Drug CDMO Services Market Drivers
2.3.3 Oligonucleotide Drug CDMO Services Market Challenges
2.3.4 Oligonucleotide Drug CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue
3.1.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue (2021–2026)
3.1.2 Global Oligonucleotide Drug CDMO Services Revenue Market Share by Players (2021–2026)
3.2 Global Top Oligonucleotide Drug CDMO Services Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide Drug CDMO Services Revenue
3.4 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio
3.4.1 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Drug CDMO Services Revenue in 2025
3.5 Global Key Players of Oligonucleotide Drug CDMO Services Head Offices and Areas Served
3.6 Global Key Players of Oligonucleotide Drug CDMO Services, Products and Applications
3.7 Global Key Players of Oligonucleotide Drug CDMO Services, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Oligonucleotide Drug CDMO Services Breakdown Data by Type
4.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Type (2021–2026)
4.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (2027–2032)
5 Oligonucleotide Drug CDMO Services Breakdown Data by Application
5.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Application (2021–2026)
5.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Oligonucleotide Drug CDMO Services Market Size (2021–2032)
6.2 North America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
6.4 North America Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Drug CDMO Services Market Size (2021–2032)
7.2 Europe Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
7.4 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size (2021–2032)
8.2 Asia-Pacific Oligonucleotide Drug CDMO Services Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2021–2026)
8.4 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Oligonucleotide Drug CDMO Services Market Size (2021–2032)
9.2 Latin America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
9.4 Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size (2021–2032)
10.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
10.4 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Oligonucleotide Drug CDMO Services Introduction
11.1.4 Bachem Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.1.5 Bachem Recent Development
11.2 WuXi TIDES
11.2.1 WuXi TIDES Company Details
11.2.2 WuXi TIDES Business Overview
11.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Introduction
11.2.4 WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.2.5 WuXi TIDES Recent Development
11.3 Ajinomoto Co
11.3.1 Ajinomoto Co Company Details
11.3.2 Ajinomoto Co Business Overview
11.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Introduction
11.3.4 Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.3.5 Ajinomoto Co Recent Development
11.4 Waters
11.4.1 Waters Company Details
11.4.2 Waters Business Overview
11.4.3 Waters Oligonucleotide Drug CDMO Services Introduction
11.4.4 Waters Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.4.5 Waters Recent Development
11.5 AGC Biologics
11.5.1 AGC Biologics Company Details
11.5.2 AGC Biologics Business Overview
11.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Introduction
11.5.4 AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.5.5 AGC Biologics Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Introduction
11.6.4 Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.6.5 Merck KGaA Recent Development
11.7 EUROAPI
11.7.1 EUROAPI Company Details
11.7.2 EUROAPI Business Overview
11.7.3 EUROAPI Oligonucleotide Drug CDMO Services Introduction
11.7.4 EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.7.5 EUROAPI Recent Development
11.8 CordenPharma
11.8.1 CordenPharma Company Details
11.8.2 CordenPharma Business Overview
11.8.3 CordenPharma Oligonucleotide Drug CDMO Services Introduction
11.8.4 CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.8.5 CordenPharma Recent Development
11.9 Cytiva
11.9.1 Cytiva Company Details
11.9.2 Cytiva Business Overview
11.9.3 Cytiva Oligonucleotide Drug CDMO Services Introduction
11.9.4 Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.9.5 Cytiva Recent Development
11.10 TriLink BioTechnologies
11.10.1 TriLink BioTechnologies Company Details
11.10.2 TriLink BioTechnologies Business Overview
11.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Introduction
11.10.4 TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.10.5 TriLink BioTechnologies Recent Development
11.11 Medicilon
11.11.1 Medicilon Company Details
11.11.2 Medicilon Business Overview
11.11.3 Medicilon Oligonucleotide Drug CDMO Services Introduction
11.11.4 Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.11.5 Medicilon Recent Development
11.12 General Biol
11.12.1 General Biol Company Details
11.12.2 General Biol Business Overview
11.12.3 General Biol Oligonucleotide Drug CDMO Services Introduction
11.12.4 General Biol Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.12.5 General Biol Recent Development
11.13 BioSpring
11.13.1 BioSpring Company Details
11.13.2 BioSpring Business Overview
11.13.3 BioSpring Oligonucleotide Drug CDMO Services Introduction
11.13.4 BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.13.5 BioSpring Recent Development
11.14 Bio-Synthesis Inc
11.14.1 Bio-Synthesis Inc Company Details
11.14.2 Bio-Synthesis Inc Business Overview
11.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Introduction
11.14.4 Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.14.5 Bio-Synthesis Inc Recent Development
11.15 Aurisco
11.15.1 Aurisco Company Details
11.15.2 Aurisco Business Overview
11.15.3 Aurisco Oligonucleotide Drug CDMO Services Introduction
11.15.4 Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.15.5 Aurisco Recent Development
11.16 Suzhou Olipharma Co.,Ltd
11.16.1 Suzhou Olipharma Co.,Ltd Company Details
11.16.2 Suzhou Olipharma Co.,Ltd Business Overview
11.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Introduction
11.16.4 Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.16.5 Suzhou Olipharma Co.,Ltd Recent Development
11.17 Porton
11.17.1 Porton Company Details
11.17.2 Porton Business Overview
11.17.3 Porton Oligonucleotide Drug CDMO Services Introduction
11.17.4 Porton Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.17.5 Porton Recent Development
11.18 RIBOPharm
11.18.1 RIBOPharm Company Details
11.18.2 RIBOPharm Business Overview
11.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Introduction
11.18.4 RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.18.5 RIBOPharm Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Bachem
WuXi TIDES
Ajinomoto
Waters
AGC Biologics
Merck KGaA
EUROAPI
CordenPharma
Cytiva
TriLink BioTechnologies
Medicilon
General Biol
Biospring
Bio-Synthesis, Inc.
Aurisco
Porton
Suzhou Olipharma Co.,Ltd
RIBOPharm
List of Tables
 Table 1. Global Oligonucleotide Drug CDMO Services Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of API
 Table 3. Key Players of Preparation
 Table 4. Global Oligonucleotide Drug CDMO Services Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million), 2021–2026
 Table 7. Global Oligonucleotide Drug CDMO Services Market Share by Region (2021–2026)
 Table 8. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global Oligonucleotide Drug CDMO Services Market Share by Region (2027–2032)
 Table 10. Oligonucleotide Drug CDMO Services Market Trends
 Table 11. Oligonucleotide Drug CDMO Services Market Drivers
 Table 12. Oligonucleotide Drug CDMO Services Market Challenges
 Table 13. Oligonucleotide Drug CDMO Services Market Restraints
 Table 14. Global Oligonucleotide Drug CDMO Services Revenue by Players (US$ Million), 2021–2026
 Table 15. Global Oligonucleotide Drug CDMO Services Market Share by Players (2021–2026)
 Table 16. Global Top Oligonucleotide Drug CDMO Services Players by Tier (Tier 1, Tier 2, and Tier 3), based on Oligonucleotide Drug CDMO Services Revenue, 2025
 Table 17. Ranking of Global Top Oligonucleotide Drug CDMO Services Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by Oligonucleotide Drug CDMO Services Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of Oligonucleotide Drug CDMO Services, Headquarters and Area Served
 Table 20. Global Key Players of Oligonucleotide Drug CDMO Services, Products and Applications
 Table 21. Global Key Players of Oligonucleotide Drug CDMO Services, Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global Oligonucleotide Drug CDMO Services Market Size by Type (US$ Million), 2021–2026
 Table 24. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2021–2026)
 Table 25. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2027–2032)
 Table 27. Global Oligonucleotide Drug CDMO Services Market Size by Application (US$ Million), 2021–2026
 Table 28. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2021–2026)
 Table 29. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2027–2032)
 Table 31. North America Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
 Table 33. North America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
 Table 46. Bachem Company Details
 Table 47. Bachem Business Overview
 Table 48. Bachem Oligonucleotide Drug CDMO Services Product
 Table 49. Bachem Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 50. Bachem Recent Development
 Table 51. WuXi TIDES Company Details
 Table 52. WuXi TIDES Business Overview
 Table 53. WuXi TIDES Oligonucleotide Drug CDMO Services Product
 Table 54. WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 55. WuXi TIDES Recent Development
 Table 56. Ajinomoto Co Company Details
 Table 57. Ajinomoto Co Business Overview
 Table 58. Ajinomoto Co Oligonucleotide Drug CDMO Services Product
 Table 59. Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 60. Ajinomoto Co Recent Development
 Table 61. Waters Company Details
 Table 62. Waters Business Overview
 Table 63. Waters Oligonucleotide Drug CDMO Services Product
 Table 64. Waters Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 65. Waters Recent Development
 Table 66. AGC Biologics Company Details
 Table 67. AGC Biologics Business Overview
 Table 68. AGC Biologics Oligonucleotide Drug CDMO Services Product
 Table 69. AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 70. AGC Biologics Recent Development
 Table 71. Merck KGaA Company Details
 Table 72. Merck KGaA Business Overview
 Table 73. Merck KGaA Oligonucleotide Drug CDMO Services Product
 Table 74. Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 75. Merck KGaA Recent Development
 Table 76. EUROAPI Company Details
 Table 77. EUROAPI Business Overview
 Table 78. EUROAPI Oligonucleotide Drug CDMO Services Product
 Table 79. EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 80. EUROAPI Recent Development
 Table 81. CordenPharma Company Details
 Table 82. CordenPharma Business Overview
 Table 83. CordenPharma Oligonucleotide Drug CDMO Services Product
 Table 84. CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 85. CordenPharma Recent Development
 Table 86. Cytiva Company Details
 Table 87. Cytiva Business Overview
 Table 88. Cytiva Oligonucleotide Drug CDMO Services Product
 Table 89. Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 90. Cytiva Recent Development
 Table 91. TriLink BioTechnologies Company Details
 Table 92. TriLink BioTechnologies Business Overview
 Table 93. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product
 Table 94. TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 95. TriLink BioTechnologies Recent Development
 Table 96. Medicilon Company Details
 Table 97. Medicilon Business Overview
 Table 98. Medicilon Oligonucleotide Drug CDMO Services Product
 Table 99. Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 100. Medicilon Recent Development
 Table 101. General Biol Company Details
 Table 102. General Biol Business Overview
 Table 103. General Biol Oligonucleotide Drug CDMO Services Product
 Table 104. General Biol Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 105. General Biol Recent Development
 Table 106. BioSpring Company Details
 Table 107. BioSpring Business Overview
 Table 108. BioSpring Oligonucleotide Drug CDMO Services Product
 Table 109. BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 110. BioSpring Recent Development
 Table 111. Bio-Synthesis Inc Company Details
 Table 112. Bio-Synthesis Inc Business Overview
 Table 113. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product
 Table 114. Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 115. Bio-Synthesis Inc Recent Development
 Table 116. Aurisco Company Details
 Table 117. Aurisco Business Overview
 Table 118. Aurisco Oligonucleotide Drug CDMO Services Product
 Table 119. Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 120. Aurisco Recent Development
 Table 121. Suzhou Olipharma Co.,Ltd Company Details
 Table 122. Suzhou Olipharma Co.,Ltd Business Overview
 Table 123. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product
 Table 124. Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 125. Suzhou Olipharma Co.,Ltd Recent Development
 Table 126. Porton Company Details
 Table 127. Porton Business Overview
 Table 128. Porton Oligonucleotide Drug CDMO Services Product
 Table 129. Porton Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 130. Porton Recent Development
 Table 131. RIBOPharm Company Details
 Table 132. RIBOPharm Business Overview
 Table 133. RIBOPharm Oligonucleotide Drug CDMO Services Product
 Table 134. RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
 Table 135. RIBOPharm Recent Development
 Table 136. Research Programs/Design for This Report
 Table 137. Key Data Information from Secondary Sources
 Table 138. Key Data Information from Primary Sources
 Table 139. Authors List of This Report


List of Figures
 Figure 1. Oligonucleotide Drug CDMO Services Picture
 Figure 2. Global Oligonucleotide Drug CDMO Services Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Oligonucleotide Drug CDMO Services Market Share by Type: 2025 vs 2032
 Figure 4. API Features
 Figure 5. Preparation Features
 Figure 6. Global Oligonucleotide Drug CDMO Services Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global Oligonucleotide Drug CDMO Services Market Share by Application: 2025 vs 2032
 Figure 8. SME Pharmaceutical Company Case Studies
 Figure 9. Large Pharmaceutical Company Case Studies
 Figure 10. Oligonucleotide Drug CDMO Services Report Years Considered
 Figure 11. Global Oligonucleotide Drug CDMO Services Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 12. Global Oligonucleotide Drug CDMO Services Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Oligonucleotide Drug CDMO Services Market Share by Region: 2025 vs 2032
 Figure 14. Global Oligonucleotide Drug CDMO Services Market Share by Players in 2025
 Figure 15. Global Oligonucleotide Drug CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 16. The Top 10 and 5 Players Market Share by Oligonucleotide Drug CDMO Services Revenue in 2025
 Figure 17. North America Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 18. North America Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
 Figure 19. United States Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. Canada Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. Europe Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Europe Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
 Figure 23. Germany Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. France Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. U.K. Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. Italy Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. Russia Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Ireland Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Region (2021–2032)
 Figure 31. China Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Japan Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. South Korea Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Southeast Asia Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. India Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Australia & New Zealand Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Latin America Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Latin America Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
 Figure 39. Mexico Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Brazil Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
 Figure 43. Israel Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Saudi Arabia Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. UAE Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Bachem Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 47. WuXi TIDES Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 48. Ajinomoto Co Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 49. Waters Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 50. AGC Biologics Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 51. Merck KGaA Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 52. EUROAPI Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 53. CordenPharma Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 54. Cytiva Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 55. TriLink BioTechnologies Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 56. Medicilon Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 57. General Biol Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 58. BioSpring Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 59. Bio-Synthesis Inc Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 60. Aurisco Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 61. Suzhou Olipharma Co.,Ltd Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 62. Porton Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 63. RIBOPharm Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Oligonucleotide CDMO Market Research Report 2025
Global Small Molecule Drug CDMO Services Market Research Report 2024
Global Antibody Drug CDMO Service Market Research Report 2024
Global mRNA CDMO Service Market Research Report 2024
Global Cell and Gene Therapy CDMO Services Market Research Report 2024
Global Plasmid DNA CDMO Service Market Research Report 2024
Global Full Service CDMO Market Research Report 2024
Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025
Global Chemical CDMO Market Research Report 2024
Global Biopharmaceutical CDMO Service Market Research Report 2024
Pharmaceutical CDMO Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Viral Vector Manufacturing CDMO Services Market Research Report 2024
Global Formulation CDMO Services Market Research Report 2024
Global Contract Dose Manufacturing Market Insights Forecast to 2030
Global Pharmaceutical CDMO Market Research Report 2025
Global Small Molecules CDMO Services Market Research Report 2024
Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cell Therapy CDMO Services Market Research Report 2025
Global Peptide Synthesis CDMO Services Market Research Report 2024
Global Aptamer CDMO Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions